Dr. Eugene B. Cone, M.D.

Medicare patients and services

Medicare patients, 2024

659

Services billed

16,441

Patients’ average age

75

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 26 companies reported 89 payments worth $56,544 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Indiana →

Industry-funded research

Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $765,867 in research payments for these studies, mostly to the institutions running them.

• A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
  Janssen Research & Development, LLC
• A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
  AstraZeneca Pharmaceuticals LP
• Phase 1 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants with Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer and Selected FGFR Mutations or Fusions
  Janssen Research & Development, LLC
• A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible …
  Janssen Research & Development, LLC
• A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)
  Janssen Research & Development, LLC
• Pylarify pet-ct or pet-mri in men with favorable intermediate risk -fir- prostate cancer -mirror
  Progenics Pharmaceuticals, Inc.
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
  Sumitomo Pharma America, Inc. · Completed · NCT05605964
• A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterio…
  Janssen Research & Development, LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Greenwood

• Glen A. Brunk, M.D.
• James W. Faulkner III, MD
• David A. Gilley, MD
• William T. Jones, M.D.
• Weston R. Kitley, MD
• Brian Orr, MD
• Bradley G. Orris, M.D.
• James H. Raybourn III, M.D.